dcb.

DCB (3,3'-dichlorobenzaldazine) is an allosteric ligand for mGluR5 and shows the negative modulatory effect of 3,3′-dimethoxybenzaldazine (DMeOB). DCB blocks the positive allosteric regulation of mGluRs with the help of 3,3′-difluorobenzaldazine (DFB).

Z-Asp-CH2-DCB is an irreversible inhibitor of broad-spectrum caspases.

L594881, also known as 3',4'-Dichlorobenzamil or DCB, is an inhibitor of Na+/Ca2+ exchanger, Na+ transport and sarcoplasmic reticulum Ca2+ release channels. L594881 can inhibit Na+/Ca2+ exchanger, Na+ transport and sarcoplasmic reticulum Ca2+ release channels.

Tylophorine analog DCB-3503 is a potential anticancer and immunosuppressive agent. DCB-3503 suppresses the translation of cellular regulatory proteins, including cyclin D1, at the elongation step. DCB-3503 allosterically regulates the ATPase and chaperone activities of HSC70 by promoting ATP hydrolysis in the presence of specific RNA binding motifs (AUUUA) of cyclin D1 mRNA.

Chlorthiamid is a herbicide.

DCBCI0901 is an inhibitor of phosphatidylinositide 3-kinase (PI3K), raptor-mTOR (mTOR complex 1 or mTORC1) and rictor-mTOR (mTOR complex 2 or mTORC2) with potential antineoplastic activity.

m-Chloro-DCBA is a bioactive chemical.

m-Fluoro-DCBA is a bioactive chemical

DC-BPi-11, a potent inhibitor of the bromodomain PHD finger transcription factor (BPTF), exhibits significant anti-proliferative effects against leukemia cells with an IC50 value of 698 nM.

DC-BPi-03 is a potent BPTF-BRD inhibitor, exhibiting an IC50 of 698.3 nM and a Kd of 2.81 μM.

DC-BPi-11 hydrochloride is a BPTF (bromodomain PHD finger transcription factor) inhibitor with an IC50 value of 698 nM, demonstrating significant anti-proliferative effects on leukemia cells [1].

DCBA, an endogenous metabolite of the insect repellent N-N-diethyl-meta-toluamide (DEET), is utilized to evaluate DEET exposure through its concentration levels in urine.

dCBP-1 is a chemical degrader of p300/CBP. dCBP-1 hijacks the E3 ubiquitin ligase CRBN for selective degradation of p300/CBP. Degradation of p300/CBP by dCBP-1 leads to effective multiple myeloma cell killing.

DCBY02 represents a highly specialized humanized monoclonal antibody specifically engineered to target the human CD93 (C1qR1) receptor with exceptional binding affinity. It effectively facilitates the measurable normalization of tumor vasculature by blocking the interaction between CD93 and its ligands, such as IGFBP7 and MMRN2, across various preclinical experimental models to evaluate the reduction of intratumoral hypoxia and the enhancement of T-cell infiltration during strictly monitored laboratory observation periods and functional immuno-normalization assays to ensure high experimental sensitivity.

Anti-DCBLD2/ESDN Antibody (FA19-1) is a humanized monoclonal antibody targeting Discoidin, CUB and LCCL domain-containing protein 2 (DCBLD2/ESDN/CLCP1). DCBLD2 is a type I transmembrane protein overexpressed in various malignancies (e.g., lung adenocarcinoma, glioma) and acts as a signal relay for growth factor signaling like EGFR. FA19-1 specifically binds to the extracellular domain of DCBLD2, blocking its mediated signaling—such as AKT activation or cisplatin-induced EMT—thereby inhibiting tumor cell migration, invasion, and distant metastasis.

Anti-DCBLD2CLCP1 Antibody (FA19-1) is a human monoclonal antibody (mAb) specifically targeting DCBLD2.

Nucleoside phosphonamidite;Fluoro-modified nucleosides;2'-Modified nucleosides

Tylophorine, (-)- is a biomedical.

OPC-167832 is a potent and orally active dprE1 Inhibitor with an IC50 of 0.258 μM. OPC-167832 has antituberculosis activity and can be used for the research of tuberculosis caused by Mycobacterium tuberculosis[1]. OPC-167832 exhibits very low MICs against laboratory strains of M. tuberculosis H37Rv (MIC: 0.0005 μg/ml) and Kurono (MIC: 0.0005 μg/ml) and strains with monoresistance to rifampin (RIF), isoniazid (INH), ethambutol (EMB), streptomycin (STR), and pyrazinamide (PZA) (MIC: 0.00024-0.001 μg/ml). However, OPC-167832 has minimal or no activity against standard strains of nonmycobacterial aerobic and anaerobic bacteria[1].The IC90 values of OPC-167832 against intracellular M. tuberculosis strains H37Rv and Kurono are 0.0048 and 0.0027 μg/ml, respectively. OPC-167832 shows bactericidal activity against intracellular M. tuberculosis at a low concentration, and the bactericidal activity is saturated at concentrations of 0.004 μg/ml or higher[1]. OPC-167832 (oral administration; 0.625-10 mg/kg) exhibits a good pharmacokinetic characteristic. The plasma reaches peak at 0.5 h to 1.0 h (tmax) and is eliminated with a half-life (t1/2) of 1.3 h to 2.1 h OPC-167832 distribution in the lungs is approximately 2 times higher than that in plasma, and the Cmax and AUCt of OPC-167832 in plasma and the lungs shows dose dependency[1].OPC-167832 (oral administration; 0.625-10 mg/kg; 4 weeks) significantly reduces lung CFU compared to the vehicle group. The dose-dependent decrease of lung CFU is observed from 0.625 mg/kg to 2.5 mg/kg. In a M. tuberculosis Kurono-infected ICR female mice model. OPC-167832 combines with DMD, BDQ, or LVX via oral gavage exhibits significantly higher efficacies than each single agent alone[1].[1].OPC-167832 (oral gavage; 2.5 mg/kg; combination with DCMB; 12 weeks) demonstrates the most potent efficacy when compares with DC, DCB. The lung CFU count after 6 weeks of treatment is below the detection limit, and at the end of just 8 weeks of treatment, the bacteria in the lungs of all the evaluated mice had already been eradicate[1]. [1]. Norimitsu Hariguchi, et al. OPC-167832, a Novel Carbostyril Derivative with Potent Antituberculosis Activity as a DprE1 Inhibitor.Antimicrob Agents Chemother. 2020 May 21;64(6):e02020-19.